Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OctaAlpha1 vs Glassia in Alpha-1-antitrypsin Deficiency
NCT03385395Phase 2Withdrawn
- Sponsor
- Octapharma
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Octapharma. Planned start Jul 2018; status: withdrawn.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03385395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385395.